Publication Name	World Journal of Gastroenterology
Manuscript ID	74589
Country	United States

Received	2021-12-29 03:11
Peer-Review Started	2021-12-29 03:12
To Make the First Decision
Return for Revision	2022-03-10 05:38
Revised	2022-03-25 03:06
Second Decision	2022-04-29 03:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-04-30 07:34
Articles in Press	2022-04-30 07:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-05-25 08:38
Publish the Manuscript Online	2022-06-16 13:07

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Tarik Silk, Mikhail Silk and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyulangone.org
Key Words	Chemoembolization; Hepatocellular carcinoma; Immunotherapy; Drug combinations; Review; Medical oncology
Core Tip	Barcelona clinic liver cancer intermediate stage disease that exceeds “the up to seven” criteria, especially with lesions larger than 5 cm, is less likely to respond to transarterial chemoembolization (TACE) alone and is therefore a disease that may respond better to systemic therapy. The use of “the up to seven” criteria can be a helpful guidepost for when to consider systemic therapy alone or in addition to TACE. With the recent breakthroughs in immunotherapy for advanced hepatocellular carcinoma which clearly demonstrated overall survival advantage over single agent tyrosine kinase inhibitors sorafenib, it is promising that the use of immunotherapy would likely lead to better outcome when used in intermediate disease.
Publish Date	2022-06-16 13:07
Citation	Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23):2561-2568
URL	https://www.wjgnet.com/1007-9327/full/v28/i23/2561.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i23.2561

Full Article (PDF)	WJG-28-2561.pdf
Full Article (Word)	WJG-28-2561.docx
Manuscript File	74589_Auto_Edited.docx
Answering Reviewers	74589-Answering reviewers.pdf
Audio Core Tip	74589-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	74589-Conflict-of-interest statement.pdf
Copyright License Agreement	74589-Copyright license agreement.pdf
Peer-review Report	74589-Peer-review(s).pdf
Scientific Misconduct Check	74589-Bing-Fan JR-2.png
Scientific Editor Work List	74589-Scientific editor work list.pdf